{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:26:26Z","timestamp":1789079186788,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41409-018-0304-4","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T15:02:20Z","timestamp":1534777340000},"page":"674-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-7857","authenticated-orcid":false,"given":"Kimikazu","family":"Yakushijin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-5496","authenticated-orcid":false,"given":"Hiromasa","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5878","authenticated-orcid":false,"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Oyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishikazu","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"304_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011;17:1713\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"304_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"304_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"304_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/17474124.2017.1370372","volume":"11","author":"S Corbacioglu","year":"2017","unstructured":"Corbacioglu S, Richardson PG. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Expert Rev Gastroenterol Hepatol. 2017;11:885\u201398.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"304_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant. 2016;51:403\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","volume":"45","author":"KJ Palmer","year":"1993","unstructured":"Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs. 1993;45:259\u201394.","journal-title":"Drugs"},{"key":"304_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444\u201357.","journal-title":"Br J Haematol"},{"key":"304_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bmt.2016.300","volume":"52","author":"AH Al Jefri","year":"2017","unstructured":"Al Jefri AH, Abujazar H, Al-Ahmari A, Al Rawas A, Al Zahrani Z, Alhejazi A, et al. Veno-occlusive disease\/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East\/North Africa regional consensus on prevention, diagnosis and management. Bone Marrow Transplant. 2017;52:588\u201391.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365.","journal-title":"Blood"},{"key":"304_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","volume":"22","author":"S Corbacioglu","year":"2016","unstructured":"Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"key":"304_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0037-1615902","volume":"82","author":"I Maruyama","year":"1999","unstructured":"Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost. 1999;82:718\u201321.","journal-title":"Thromb Haemost"},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31\u201341.","journal-title":"J Thromb Haemost"},{"key":"304_CR15","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/CCM.0b013e31828e9b03","volume":"41","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069\u201379.","journal-title":"Crit Care Med"},{"key":"304_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1160\/TH15-12-0987","volume":"115","author":"M Hayakawa","year":"2016","unstructured":"Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115:1157\u201366.","journal-title":"Thromb Haemost"},{"key":"304_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2009.217","volume":"45","author":"T Ikezoe","year":"2010","unstructured":"Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010;45:783\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/ajh.22137","volume":"86","author":"C Ohwada","year":"2011","unstructured":"Ohwada C, Takeuchi M, Kawaguchi T, Tsukamoto S, Sakai S, Takeda Y, et al. Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome\/hepatic veno-occlusive disease after bone marrow transplantation. Am J Hematol. 2011;86:886\u20138.","journal-title":"Am J Hematol"},{"key":"304_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/bmt.2011.103","volume":"47","author":"D Nakamura","year":"2012","unstructured":"Nakamura D, Yoshimitsu M, Kawada H, Inoue H, Kuroki T, Kaieda T, et al. Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47:463\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000343194","volume":"129","author":"S Yamamoto","year":"2013","unstructured":"Yamamoto S, Yagawa A, Toyama D, Akiyama K, Hayashi M, Mabuchi M, et al. Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin. Acta Haematol. 2013;129:62\u20134.","journal-title":"Acta Haematol"},{"key":"304_CR21","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/bmt.2016.179","volume":"51","author":"J Inagaki","year":"2016","unstructured":"Inagaki J, Kurauchi K, Fukano R, Noguchi M, Okamura J. Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation. Bone Marrow Transplant. 2016;51:1543\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-014-0050-7","volume":"3","author":"T Ikezoe","year":"2015","unstructured":"Ikezoe T. Thrombomodulin\/activated protein C system in septic disseminated intravascular coagulation. J Intensive Care. 2015;3:1.","journal-title":"J Intensive Care"},{"key":"304_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","volume":"16","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2010;16:1005\u201317.","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"304_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1160\/TH16-07-0547","volume":"117","author":"M Hayakawa","year":"2017","unstructured":"Hayakawa M, Kushimoto S, Watanabe E, Goto K, Suzuki Y, Kotani T, et al. Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction. Thromb Haemost. 2017;117:851\u20139.","journal-title":"Thromb Haemost"},{"key":"304_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","volume":"33","author":"S Corbacioglu","year":"2004","unstructured":"Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"304_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14727","volume":"178","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112\u20138.","journal-title":"Br J Haematol"},{"key":"304_CR28","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"SI Bearman","year":"1997","unstructured":"Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501\u20136.","journal-title":"Blood"},{"key":"304_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/bmt.2010.229","volume":"46","author":"M Tsubokura","year":"2011","unstructured":"Tsubokura M, Yamashita T, Inagaki L, Kobayashi T, Kakihana K, Wakabayashi S, et al. Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation. Bone Marrow Transplant. 2011;46:1030\u20131.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0304-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:53Z","timestamp":1684617173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0304-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0304-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]},"assertion":[{"value":"19 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KY received honoraria from Asahi-kasei Pharma, JAZZ Pharmaceuticals, and Pfizer Inc. TI received grant\/research support from Asahi-kasei Pharma. YU received research funding and travel expense fee from Kainos Laboratories Inc., Ablynx NV., and Eli Lilly Japan, outside submitted work. AK received grant\/research support from JAZZ Pharmaceuticals and Nippon Shinyaku Co., Ltd. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}